Home Companies Catalysts Deep Dives
Deltyba delamanid APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaInfectious Disease
Launch2014-04-01
Peak Sales Est$100M
Formulations[{"id":"deltyba-oral","route":"ORAL","device":"Tablet (50mg)","setting":"HCP_ONLY","frequency":"Twic
Companies
4578 (ORIGINATOR)100%
Mechanism: Mycolic Acid Synthesis Inhibitor
Expert: Inhibits methoxy-mycolic acid and keto-mycolic acid synthesis in the mycobacterial cell wall via inhibition of the F420-dependent pathway. Novel mechanism distinct from isoniazid, active against MDR-TB strains.
Everyday: Blocks the TB bacterium from making mycolic acid — a waxy coating that makes TB notoriously hard to kill. Strip away this armor and the bacterium becomes defenseless.
Targets: []
Programs (1)
IndicationStageKey StudyRegional Status
MDR-TBAPPROVEDTrial 204/213[{"stage":"APPROVED","region":"EU","approval_date":"2014-04-28"},{"stage":"APPRO
Notes
Otsuka-discovered. One of first new anti-TB drugs in 40 years. WHO Essential Medicines List. Available in 120+ countries.
Data from Supabase · Updated 2026-03-24